Table 2.

Urine parameters of Bern ADPKD registry participants at 1-year follow-up

	No Tolvaptan (n=61)		Tolvaptan (n=27)
Urine Parameter	1-Yr Follow-Up	Difference from 1-Yr Follow-Up to Baseline	1-Yr Follow-Up	Difference from 1-Yr Follow-Up to Baseline
Relative supersaturation ratio calcium oxalate	2.9; 1.8–4.5, [4]	−0.10; −0.93–1.04, [7]	1.4; 0.6–1.7	−1.6; −3.1–0.063, [1]
Relative supersaturation ratio brushite	0.67; 0.17–1.3, [4]	0.060; −0.090–0.49, [7]	0.13; 0.085–0.4	−0.080; −0.26–0.020, [1]
Relative supersaturation ratio uric acid	0.59; 0.25–1.59, [4]	−0.12; −0.60–0.29, [7]	0.22; 0.085–0.54	−0.69; −1.4–−0.25, [1]
Urine calcium/creatinine ratio, mmol/mmol per d	0.27; 0.18–0.43, [2]	−0.010; −0.030–0.070, [2]	0.15; 0.08–0.32	0; −0.065–0.060
Urine phosphate/creatinine ratio, mmol/mmol per d	2.1; 1.8–2.4, [2]	0.15; −0.17–0.37, [2]	1.7; 1.4–2	−0.18; −0.44–0.20
Urine magnesium/creatinine ratio, mmol/mmol per d	0.32; 0.24–0.43, [2]	0.020; −0.060–0.080, [3]	0.32; 0.26–0.39	0.030; 0.010–0.080
Urine uric acid/creatinine ratio, mmol/mmol per d	0.23; 0.20–0.27, [2]	0.010; −0.020–0.040, [3]	0.20; 0.16–0.23	0; −0.035–0.035
Urine oxalate/creatinine ratio, mmol/mmol per d	0.030; 0.020–0.040, [2]	0; −0.010–0.010, [4]	0.03; 0.03–0.04	0; 0–0.010
Urine citrate/creatinine ratio, mmol/mmol per d	0.16; 0.065–0.22, [2]	0; −0.030–0.030, [3]	0.11; 0.065–0.17	0.010; −0.015–0.055
Urine sulfate/creatinine ratio, mmol/mmol per d	1.5; 1.3–1.8, [2]	0.11; −0.090–0.37, [4]	1.5; 1.2–1.9	0.11; −0.22–0.29, [1]
Urine pH	6.1; 5.4–6.5, [4]	0.060; −0.21–0.41, [6]	6.1; 5.7–6.5	0.33; 0.17–0.58
Urine ammonium/creatinine ratio, mmol/mmol per d	2.0; 1.6–2.4, [3]	−0.12; −0.45–0.41, [5]	1.7; 1.3–1.9	−0.41; −0.78–−0.030, [2]
Urine titratable acidity/creatinine ratio, mEq/mmol per d	1.4; 0.89–1.7, [4]	−0.058; −0.36–0.29, [7]	1; 0.69–1.4	−0.24; −0.75–0.043, [1]
Urine NAE/creatinine ratio, mEq/mmol per d	1.3; 0.60–1.6, [4]	−0.12; −0.77–0.28, [8]	1.1; 0.43–1.5, [2]	−0.72; −1.3–−0.46, [6]
Urine NGIA/creatinine ratio, mEq/mmol per d	4.3; 2.9–5.8, [2]	−0.22; −0.95–1.7, [5]	4.7; 3.9–7, [1]	1.8; 0.64–3.7, [4]
Urine volume, L/d	2.5; 1.6–3.0, [2]	0.62; −0.34–0.34, [2]	5.2; 3.9–5.9	2.6; 1.4–3.3
Plasma copeptin, pmol/L	5.1; 3.1 –12	0.34; −1.1–1.4, [12]	22; 19–31, [1]	16; 8.8–22, [5]

One-year follow-up 24-h urine data were available for a total of 88 participants; 61 participants without and 27 participants with Tolvaptan treatment. Differences in 1-yr follow-up to baseline are indicated for each subgroup. Continuous variables are described by their median and 25th–75th percentiles. Numbers in square brackets indicate numbers of participants with missing data for corresponding variables. NAE, net acid excretion; NGIA, net gastrointestinal alkali absorption.